Objective To investigate the difference of efficacy between Shengxuening and polysaccharide iron complex capsule in treating renal anemia in patients with hemodialysis. Methods A total of 50 cases of hemodialysis patients with renal anemia, who underwent hemodialysis regularly in blood purification center of Hefei Fifth People’s Hospital, were selected and randomly divided into observation group and control group, with 25 cases in each group. The treatment group was given Shengxuening tablets combined with erythropoietin and the control group given polysaccharide iron complex capsule combined with erythropoietin, with a treatment course of 12 weeks. Hemoglobin(Hb), hematocrit(Hct), serum ferritin(SF), and transferrin saturation(TSAT) were detected before treatment and at 4 weeks, 8 weeks and 12 weeks of the treatment.Results After 12 weeks, the indices were compared between the control treatment and the treatment group. Serum Hb, Hct, SF and TAST all increased significantly(P<0.05). The changes of the indices were more obvious. Compared to the control group, serum Hb, Hct, SF and TAST in the treatment group had statistically significant changes after treatment(P<0.05). Conclusions Shengxuening tablets can significantly improve hemoglobin, hematocrit, SF and TSAT in hemodialysis patients, promote iron absorption and utilization, increase iron storage in the body, and reduce iron consumption. Its efficacy for treatment of treating renal anemia in hemodialysis patients by combing with erythropoietin is more evident than polysaccharide iron complex capsule combined with erythropoietin.

To observe the efficacy of intravenous and oral pulse administration of calcitriolin treatment of hemodialysis patients with secondary hyperparathyroidism.40 cases were divided into intravenous calcitriol group (the treatmentgroup) and oral calcitriol group (the control group). According to iPTH level, each group was divided into 2 subgroups,the treatment group 1 and the control group 1 (300 pg/ ml≤iPTH≤600 pg/ ml),the treatment group 2 and the control groups (iPTH >600 pg/ ml), and treated for 3 months. The levels of iPTH, alkaline phosphatase(AKP), serum calcium and phosphorus in the two groups were measured at 1, 2 and 3 months after treatment. After 3 months, the levels of iPTH and AKP in the four groups were significantly lower than those before treatment (P<0. 05). Compared with the control group 1, the levels of AKP and iPTH in the treatment group 1 were not statisticallysignificant (P <0. 05). Compared with control group 2, the levels of iPTH and AKP in treatment group 2 were significantly higher than those in control group 2 (P < 0. 05). Compared with oral calcitriol group, intravenous calcitriol can effectively reduce the level of iPTH and less cause hypercalcemia.

目的 观察生血宁片联合促红细胞生成素治疗维持性血液透析患者肾性贫血的疗效.方法 选取2015年1月至2016年1月合肥市第五人民医院血液净化中心维持性血液透析肾性贫血患者40例,采用随机对照方法将该40例患者随机分为两组,每组20例.两组患者均使用促红细胞生成素治疗,治疗组在此基础上加用生血宁,疗程3个月. 疗程结束后检测两组患者血红蛋白浓度(Hb)、红细胞压积水平(Hct)、 血清铁蛋白(SF) 及转铁蛋白饱和度(TSAT).结果 3个月后与治疗前相比,对照组的血清Hb(92.47±3.88)g/L、Hct(24.18±4.46)%、SF(165.2±31.68) μg/L、TAST(24.28±5.13)%均较治疗前升高,差异均有统计学意义(P<0.05);治疗组的血清Hb(115.8±±4.46) g/L、Hct(31.24±7.86)%、SF(189.2±46.68) μg/L、TAST(31.24±8.24)%均较治疗前升高,差异均有统计学意义(P<0.05);且治疗组均优于对照组,差异均有统计学意义(P<0.05).治疗组总有效率为85.0%,高于对照组 65.0%,差异有统计学意义(P<0.05).结论 生血宁片联合促红细胞生成素治疗维持性血液透析患者肾性贫血效果更优.

探讨20例奥布卡因凝胶缓解血液透析患者动静脉内瘘穿刺疼痛的疗效及穿刺前的凝胶涂擦方法以及穿刺方法。研究证明奥布卡因凝胶能减轻维持性血液透析患者动静脉内瘘穿刺时的疼痛,并且本操作简单、安全、无不良反应,适合临床推广应用。